EGFR and breast cancer: Hypothetically, clinical testing of dual inhibitors of EGFR and HER2, such as lapatinib, neratinib, and BIBW 2992 (afatinib), might thus be of particular interest in the relatively small subset of breast cancer patients whose disease first recurs in the lungs.